🇸🇪 Sweden Country × Condition
melanoma Clinical Trials in Sweden
Active clinical trials for melanoma with research sites in Sweden. All data sourced live from ClinicalTrials.gov — updated daily.
Active Trials: 2 // Recruiting: 2 Phases: Phase 1, Phase 2 // Updated: Daily
Total Trials
2
Recruiting Now
2
Country
🇸🇪 Sweden
Active Trials in Sweden (2)
NCT03685890 Phase 1, Phase 2
Recruiting
Evaluating the Effect of Nivolumab for Patients With In-transit Metastases Treated With Isolated Limb Perfusion
Enrollment
74 pts
Country
🇸🇪 Sweden
Vastra Gotaland Region
View Trial → NCT02332668 Phase 1, Phase 2
Recruiting
A Study of Pembrolizumab (MK-3475) in Pediatric Participants With an Advanced Solid Tumor or Lymphoma (MK-3475-051/KEYNOTE-051)
Enrollment
370 pts
Country
🇸🇪 Sweden
Merck Sharp & Dohme LLC
View Trial → Frequently Asked Questions
How many melanoma clinical trials are active in Sweden?
There are currently 2 active clinical trials for melanoma with sites in Sweden, of which 2 are actively recruiting patients.
How can I join a melanoma clinical trial in Sweden?
To join a melanoma clinical trial in Sweden, select a recruiting trial below and check the eligibility criteria. Contact the trial's principal investigator or the listed site in Sweden directly. All trials listed here are sourced from ClinicalTrials.gov, the official U.S. registry of clinical studies.
What phases are melanoma trials in Sweden?
Active melanoma trials in Sweden span Phase 1, Phase 2. Phase I trials test safety, Phase II test efficacy, and Phase III compare against standard treatments in larger patient populations.
ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer · Last Reviewed: November 2026 · Data Methodology